Simon Redwood Advanced Angioplasty Jan 2006

Slides:



Advertisements
Similar presentations
B alloon-pump assisted C oronary I ntervention S tudy BCIS-1 Simon Redwood Kings College London/ St Thomas Hospital Steering Committee: Divaka Perera,
Advertisements

BCIS Returns 1998 (Oct 1999) BCIS Audit Returns of Interventional Procedures 1998 Leicester, October 1999 Mark de Belder (Audit Secretary, BCIS) on behalf.
BCIS Audit Returns of Interventional Procedures 2000 Mark de Belder BCIS UK National Audit Officer on behalf of Council of the British Cardiovascular Intervention.
BBC ONE David Hildick-Smith Sussex Cardiac Centre Brighton, UK on behalf of the BBC ONE Investigators.
BIFURCATION LESIONS Dr. Tahsin.N
Coronary Revascularisation in Patients With Diabetes Mellitus Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
AA 2007 Bifurcation PCI and UK Trial Update Rosie Swallow Royal Bournemouth Hospital.
BCIS Audit Returns of Interventional Procedures 2001 Edinburgh 2002 Mark de Belder BCIS National Audit Officer on behalf of Council of the British Cardiovascular.
ARTS I & II Keith D Dawkins Southampton University Hospital.
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.
Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Coronary Artery Revascularisation
UK Trial Update Simon Redwood Advanced Angioplasty Jan 2006 No Conflict of Interest.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
B alloon-pump assisted C oronary I ntervention S tudy BCIS-1 Simon Redwood St Thomas’ Hospital / King’s College London On behalf of the BCIS-1 Investigators.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Professor Martin T Rothman Director Cardiac Research & Development Barts & The London NHS Trust London, England Professor Martin T Rothman Director Cardiac.
Heart Attack Centres: Every Network Should Have (at least) One Dr Rod Stables The Liverpool Heart and Chest Hospital.
West Hertfordshire Primary Angioplasty Service Masood Khan.
British Bifurcation Coronary Study Objective:To compare the outcome of 2 treatment strategies for bifurcation lesions. Study:Multicenter, randomized trial.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Coronary Revascularisation: the DoH View Dr Roger Boyle National Director for Heart Disease.
Treatment strategies for “stable” CAD patients: COURAGE, OAT, SWISSI II, VIAMI in perspective Pierfrancesco Agostoni, MD Antwerp Cardiovascular Institute.
AB 1/03 Non-Coronary Intervention Circulatory Support Advanced Angioplasty 2003 Andreas Baumbach Bristol Royal Infirmary.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Balloon-pump assisted Coronary Intervention Study BCIS-1 Simon Redwood Divaka Perera, Rod Stables, Martyn Thomas.
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
The OPTIMAX first-in-man study Mid-term clinical outcome of Titanium-Nitride-Oxide-coated Cobalt Chromium stents in patients with de novo coronary artery.
Disclosures Runlin Gao has received a research grant
Runlin Gao, M.D. On behalf of ABSORB China Investigators
What´s New in the Literature on Transradial Intervention
Two-year clinical outcomes in the EVOLVE FHU trial: A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Ian Meredith.
The British Heart Foundation older patients with non-ST SEgmeNt elevatIOn myocaRdial infarction Randomized Interventional TreAtment Trial The BHF SENIOR-RITA.
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
BVS Expand: First Results of Wide Clinical Applications
On behalf of J. Belardi, M. Leon, L. Mauri,
Balloon-pump assisted Coronary Intervention Study (BCIS-1):
Andrew McNeice1,2, Imad J. Nadra1,2, Simon D
Jeff Macemon Waikato Cardiothoracic Unit
Statins Evaluation in Coronary procedUres and REvascularization
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
Giuseppe Biondi Zoccai, MD
3-Year Clinical Outcomes From the RESOLUTE US Study
Preventive Angioplasty in Myocardial Infarction Trial
Randomized Comparison in the Setting of Acute MI
American Heart Association Presented by Dr. Julinda Mehilli
American College of Cardiology Presented by Dr. Michel R. Le May
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
On behalf of all principal COMPARE II investigators:
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
What oral antiplatelet therapy would you choose?
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
(A) Meta-analysis of repeat revascularisation in randomised trials.
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Atlantic Cardiovascular Patient Outcomes Research Team
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.
Presentation transcript:

Simon Redwood Advanced Angioplasty Jan 2006 UK Trial Update Simon Redwood Advanced Angioplasty Jan 2006 No Conflict of Interest

BCIS-1 Study Balloon-pump assisted Coronary Intervention Study A British Cardiovascular Intervention Society Project

IABP use during high-risk PCI n=133, elective PCI Non-randomised trial Briguori et al, Am Heart J 2003 p=0.29 p=0.001

Study Design Prospective, open, randomised trial Randomisation to Elective IABP or No Planned IABP UK study 15-20 centres Sample size 300 patients Follow-up to hospital discharge or 28 days after randomisation which ever is sooner Six month follow-up ONS / GROS BCIS-1

Inclusion Criteria Exclusion Criteria Impaired LV Function (EF < 30%) Extensive Myocardium at Risk LMS Stenosis Jeopardy Score > 8 Exclusion Criteria Cardiogenic Shock STEMI within 48 hours VSD, MR, Intractable VT/VF Contraindication to IABP BCIS-1

MACE at hospital discharge or 28 days Primary Outcome MACE at hospital discharge or 28 days Secondary Outcomes Mortality at six months Procedural complications Procedural success Bleeding complications Access site complications Transient ischaemic attack Duration of hospital stay BCIS-1

Principal Investigator Institution Principal Investigator Study Co-ordinator Birmingham Heartlands Dr Mike Pitt Juliet Hulse Edinburgh Royal Infirmary Dr Neal Uren Susan Spiers Glenfield Hospital Dr Anthony Gershlick Amanda Lloyd Kings College London Dr Martyn Thomas Joanne Gregory Liverpool CTC Dr Rod Stables Heather Rodgers Northern General Hospital Dr Julian Gunn Clare Wales Royal Victoria Hospital Dr David Roberts Lesley Radford Royal Sussex County Hospital Dr Adam de Belder Nina Cooter Royal Bournemouth General Dr Rosie Swallow Nicki Lakeman St George's Dr Stephen Brecker Sue Brown St Thomas Hospital Dr James Coutts Alison Child Southwest Cardiothoracic Centre Dr Chris Burrell Chris Burrell University Hospital of North Staffordshire Dr Jim Nolan Julie Machin Wessex CTC Dr Nick Curzen Zoe Nicholas Western Infirmary Dr Keith Oldroyd Joanne Kelly Wolverhampton Heart & Lung Centre Dr James Cotton Andy Smallwood Yorkshire Heart Centre Dr Dan Blackman Claire Priestley

Recruitment at 17th January 2006 1st patient randomised 20th Dec 06

Timelines Jan to Apr 06 Bring remaining centres on-line Apr 24th 06 Investigators Meeting BCS Dec 05 to Mar 07 Recruitment Jan 07 to Apr 07 Closeout of centres Finalise dataset May 07 Analyse data June 07 Manuscript

BBC ONE The British Bifurcation Coronary study: Old, New and Evolving strategies A randomized comparison of simple versus complex drug-eluting stenting for bifurcation lesions

BBC ONE Inclusion criteria >18 yrs Stable or unstable angina Bifurcation types I-IV suitable for stenting of both vessels Vessel diameters >2.25mm side, >2.5mm main

(according to operator preference) BBC ONE Simple – provisional T-stenting Following main vessel stenting, the side branch should not be treated further unless there is: <TIMI 3 flow in the side branch Severe ostial pinching (>90%) of the side branch Threatened side vessel closure Side-branch dissection >type A Complex – crush or culotte (according to operator preference)

Primary endpoints (9 months) BBC ONE Primary endpoints (9 months) Death Target vessel failure main vessel or side branch TIMI<3 (after vasodilators) on further angiogram main vessel or side branch undergoes attempted repeat PCI/CABG Myocardial infarction

No. Patients recruited 88 Steering committee: David Hildick-Smith Rod Stables Nick Curzen Keith Oldroyd BBC ONE Jan 2006 ACTIVE CENTRES CENTRE PI Admin Recruited Brighton H-Smith Cooter 45 Coventry Glennon Gill 13 Bristol Baumbach Singh 12 Glasgow Oldroyd Kelly 6 Wolverhpton Cotton Smallwood KingsCollege Thomas Grogory 4 Nottingham Henderson Burton 1 St George’s Brecker Brown Southampton Curzen Liverpool Stables Manchester F-Ordoubadi Stoke Butler Blackpool Roberts Oxford Banning Papworth Clarke St Thomas Redwood Dublin Mulvihill Hull Hoye Lanarkshire Gilbert Newcastle Zaman Reading Orr UCH Kennon TRIAL DESIGN | Patients with bifurcation coronary artery disease requiring PCI (main vessel ≥2.5mm, side branch ≥2.25mm) RANDOMIZED TO EITHER SIMPLE COMPLEX (Stepwise provisional T-stent) (Total lesion coverage) Primary endpoint: composite at 9 months of death, MI, TVF. 500 patients to be recruited by mid 2007. New centres welcome. Trial started Brighton January 2005 For more information, please see BBC ONE website: http://host.e-dendrite.com/csp/bbcs/FrontPages/bbcs.csp Or david.hildick-smith@bsuh.nhs.uk

BBC ONE recruitment to January 20th 2006

The CARDia Trial Coronary Artery Revascularisation in Diabetes

Study Design Primary endpoint: Multi-centre, randomised, prospective comparison of PCI vs CABG for diabetics with MV or complex SVD ‘Up-to-date’ strategy – DES, 2b3a, Arterial conduits, off-pump, optimum glucose control, etc Non Inferiority design, target 600 patients Primary endpoint: Composite event rate at 1 year of death/non-fatal MI/non-fatal stroke Major secondary: Further revascularisation procedures

Diabetic patients with multivessel disease or complex single vessel disease Suitable for PCI or CABG Inclusion and exclusion criteria met CONSENT Randomisation CABG PCI +DES No registry

CARDia Centres The 6 centres London are: Hammersmith St Mary’s Hairmyers Glasgow Western James Cook University Dublin Brighton Southampton Papworth LONDON Bristol Birmingham Nottingham Blackpool Liverpool Sheffield The 6 centres London are: Hammersmith St Mary’s St Thomas’ Kings College London Chest Harefield

If every centre recruited 1 per month we would finish in 10 months, if 2 then 5 months ! Recruitment So Far !

R-PCI mortality 5.4%

MANDATED RESCUE PCI (REACT) Chest Pain Paramedic Δ AMI Prehospital Thrombolysis 300 mg clopidogrel (CLARITY) 600 mg clopidogrel 90 min ECG < 50% ST resolution > 50% ST segment resolution PPCI MANDATED RESCUE PCI (REACT) Pre-discharge angio (GRACIA)